Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 5.82 MB
Add to list
  1. Search results
  2. Circulating microRNA biomarkers for m...

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

Fjoralba Zeka (UGent) , Anneleen Decock (UGent) , Alan Van Goethem (UGent) , Katrien Vanderheyden, Fleur Demuynck (UGent) , Tim Lammens (UGent) , Hetty Helsmoortel (UGent) , Joëlle Vermeulen, Rosa Noguera, Ana P. Berbegall, et al.
(2018) JCI INSIGHT. 3(23).
Author
Organization
Abstract
In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of noninvasive biomarkers with potential in monitoring metastatic disease, After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in 2 independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis, and overall survival revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential abundance analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in both patient cohorts. Increasing levels of these miRNAs were also observed in serum from xenografted mice bearing human neuroblastoma tumors. Moreover, murine serum miRNA levels were strongly associated with tumor volume. These findings were validated in longitudinal serum samples from metastatic neuroblastoma patients, where the 9 miRNAs were associated with disease burden and treatment response.
Keywords
SERUM, EXPRESSION, DNA, CHILDHOOD, QUALITY

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 5.82 MB

Citation

Please use this url to cite or link to this publication:

MLA
Zeka, Fjoralba, et al. “Circulating MicroRNA Biomarkers for Metastatic Disease in Neuroblastoma Patients.” JCI INSIGHT, vol. 3, no. 23, 2018, doi:10.1172/jci.insight.97021.
APA
Zeka, F., Decock, A., Van Goethem, A., Vanderheyden, K., Demuynck, F., Lammens, T., … Vandesompele, J. (2018). Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI INSIGHT, 3(23). https://doi.org/10.1172/jci.insight.97021
Chicago author-date
Zeka, Fjoralba, Anneleen Decock, Alan Van Goethem, Katrien Vanderheyden, Fleur Demuynck, Tim Lammens, Hetty Helsmoortel, et al. 2018. “Circulating MicroRNA Biomarkers for Metastatic Disease in Neuroblastoma Patients.” JCI INSIGHT 3 (23). https://doi.org/10.1172/jci.insight.97021.
Chicago author-date (all authors)
Zeka, Fjoralba, Anneleen Decock, Alan Van Goethem, Katrien Vanderheyden, Fleur Demuynck, Tim Lammens, Hetty Helsmoortel, Joëlle Vermeulen, Rosa Noguera, Ana P. Berbegall, Valérie Combaret, Gudrun Schleiermacher, Genevieve Laureys, Alexander Schramm, Johannes H. Schulte, Sven Rahmann, Julie Bienertová-Vašků, Pavel Mazánek, Marta Jeison, Shifra Ash, Michael D. Hogarty, Mirthala Moreno-Smith, Eveline Barbieri, Jason Shohet, Frank Berthold, Tom Van Maerken, Franki Speleman, Matthias Fischer, Katleen De Preter, Pieter Mestdagh, and Jo Vandesompele. 2018. “Circulating MicroRNA Biomarkers for Metastatic Disease in Neuroblastoma Patients.” JCI INSIGHT 3 (23). doi:10.1172/jci.insight.97021.
Vancouver
1.
Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, et al. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI INSIGHT. 2018;3(23).
IEEE
[1]
F. Zeka et al., “Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients,” JCI INSIGHT, vol. 3, no. 23, 2018.
@article{8591623,
  abstract     = {{In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of noninvasive biomarkers with potential in monitoring metastatic disease, After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in 2 independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis, and overall survival revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential abundance analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in both patient cohorts. Increasing levels of these miRNAs were also observed in serum from xenografted mice bearing human neuroblastoma tumors. Moreover, murine serum miRNA levels were strongly associated with tumor volume. These findings were validated in longitudinal serum samples from metastatic neuroblastoma patients, where the 9 miRNAs were associated with disease burden and treatment response.}},
  articleno    = {{e97021}},
  author       = {{Zeka, Fjoralba and Decock, Anneleen and Van Goethem, Alan and Vanderheyden, Katrien and Demuynck, Fleur and Lammens, Tim and Helsmoortel, Hetty and Vermeulen, Joëlle and Noguera, Rosa and Berbegall, Ana P. and Combaret, Valérie and Schleiermacher, Gudrun and Laureys, Genevieve and Schramm, Alexander and Schulte, Johannes H. and Rahmann, Sven and Bienertová-Vašků, Julie and Mazánek, Pavel and Jeison, Marta and Ash, Shifra and Hogarty, Michael D. and Moreno-Smith, Mirthala and Barbieri, Eveline and Shohet, Jason and Berthold, Frank and Van Maerken, Tom and Speleman, Franki and Fischer, Matthias and De Preter, Katleen and Mestdagh, Pieter and Vandesompele, Jo}},
  issn         = {{2379-3708}},
  journal      = {{JCI INSIGHT}},
  keywords     = {{SERUM,EXPRESSION,DNA,CHILDHOOD,QUALITY}},
  language     = {{eng}},
  number       = {{23}},
  pages        = {{13}},
  title        = {{Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients}},
  url          = {{http://doi.org/10.1172/jci.insight.97021}},
  volume       = {{3}},
  year         = {{2018}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: